Nuno Sevivas1,2,3,4, Fábio Gabriel Teixeira1,2, Raquel Portugal5, Bruno Direito-Santos3, João Espregueira-Mendes1,2,4,6, Filipe J Oliveira7, Rui F Silva7, Nuno Sousa1,2, Wan Ting Sow8, Luong T H Nguyen8, Kee Woei Ng8, António J Salgado1,2. 1. Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal. 2. ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. 3. Orthopaedics Department, Hospital de Braga and Hospital Privado de Braga, Braga, Portugal. 4. Clínica Espregueira-Mendes, FIFA Medical Centre of Excellence, Estádio do Dragão, Porto, Portugal. 5. Pathology Department, Hospital de São João, Porto, Portugal. 6. 3B's Research Group, Biomaterials, Biodegradables and Biomimetics, Department of Polymer Engineering, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal. 7. CICECO, Department of Materials and Ceramic Engineering, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal. 8. School of Materials Science and Engineering, Nanyang Technological University, Singapore.
Abstract
BACKGROUND: Massive rotator cuff tears (MRCTs) represent a major clinical concern, especially when degeneration and chronicity are involved, which highly compromise healing capacity. PURPOSE: To study the effect of the secretome of mesenchymal stem cells (MSCs) on tendon cells (TCs) followed by the combination of these activated TCs with an electrospun keratin-based scaffold to develop a tissue engineering strategy to improve tendon-bone interface (TBi) healing in a chronic MRCT rat model. STUDY DESIGN: Controlled laboratory study. METHODS: Human TCs (hTCs) cultured with the human MSCs (hMSCs) secretome (as conditioned media [CM]) were combined with keratin electrospun scaffolds and further implanted in a chronic MRCT rat model. Wistar-Han rats (N = 15) were randomly assigned to 1 of 3 groups: untreated lesion (MRCT group, n = 5), lesion treated with a scaffold only (scaffold-only group, n = 5), and lesion treated with a scaffold seeded with hTCs preconditioned with hMSCs-CM (STC_hMSC_CM group, n = 5). After sacrifice, 16 weeks after surgery, the rotator cuff TBi was harvested for histological analysis and biomechanical testing. RESULTS: The hMSCs secretome increased hTCs viability and density in vitro. In vivo, a significant improvement of the tendon maturing score was observed in the STC_hMSC_CM group (mean ± standard error of the mean, 15.6 ± 1.08) compared with the MRCT group (11.0 ± 1.38; P < .05). Biomechanical tests revealed a significant increase in the total elongation to rupture (STC_hMSC_CM, 11.99 ± 3.30 mm; scaffold-only, 9.89 ± 3.47 mm; MRCT, 5.86 ± 3.16 mm; P < .05) as well as a lower stiffness (STC_hMSC_CM, 6.25 ± 1.74 N/mm; scaffold-only, 6.72 ± 1.28 N/mm; MRCT, 11.54 ± 2.99 N/mm; P < .01). CONCLUSION: The results demonstrated that hMSCs-CM increased hTCs viability and density in vitro. Clear benefits also were observed when these primed cells were integrated into a tissue engineering strategy with an electrospun keratin scaffold, as evidenced by improved histological and biomechanical properties for the STC_hMSC_CM group compared with the MRCT group. CLINICAL RELEVANCE: This work supports further investigation into the use of MSC secretome for priming TCs toward a more differentiated phenotype, and it promotes the tissue engineering strategy as a promising modality to help improve treatment outcomes for chronic MRCTs.
BACKGROUND: Massive rotator cuff tears (MRCTs) represent a major clinical concern, especially when degeneration and chronicity are involved, which highly compromise healing capacity. PURPOSE: To study the effect of the secretome of mesenchymal stem cells (MSCs) on tendon cells (TCs) followed by the combination of these activated TCs with an electrospun keratin-based scaffold to develop a tissue engineering strategy to improve tendon-bone interface (TBi) healing in a chronic MRCT rat model. STUDY DESIGN: Controlled laboratory study. METHODS:HumanTCs (hTCs) cultured with the human MSCs (hMSCs) secretome (as conditioned media [CM]) were combined with keratin electrospun scaffolds and further implanted in a chronic MRCT rat model. Wistar-Han rats (N = 15) were randomly assigned to 1 of 3 groups: untreated lesion (MRCT group, n = 5), lesion treated with a scaffold only (scaffold-only group, n = 5), and lesion treated with a scaffold seeded with hTCs preconditioned with hMSCs-CM (STC_hMSC_CM group, n = 5). After sacrifice, 16 weeks after surgery, the rotator cuff TBi was harvested for histological analysis and biomechanical testing. RESULTS: The hMSCs secretome increased hTCs viability and density in vitro. In vivo, a significant improvement of the tendon maturing score was observed in the STC_hMSC_CM group (mean ± standard error of the mean, 15.6 ± 1.08) compared with the MRCT group (11.0 ± 1.38; P < .05). Biomechanical tests revealed a significant increase in the total elongation to rupture (STC_hMSC_CM, 11.99 ± 3.30 mm; scaffold-only, 9.89 ± 3.47 mm; MRCT, 5.86 ± 3.16 mm; P < .05) as well as a lower stiffness (STC_hMSC_CM, 6.25 ± 1.74 N/mm; scaffold-only, 6.72 ± 1.28 N/mm; MRCT, 11.54 ± 2.99 N/mm; P < .01). CONCLUSION: The results demonstrated that hMSCs-CM increased hTCs viability and density in vitro. Clear benefits also were observed when these primed cells were integrated into a tissue engineering strategy with an electrospun keratin scaffold, as evidenced by improved histological and biomechanical properties for the STC_hMSC_CM group compared with the MRCT group. CLINICAL RELEVANCE: This work supports further investigation into the use of MSC secretome for priming TCs toward a more differentiated phenotype, and it promotes the tissue engineering strategy as a promising modality to help improve treatment outcomes for chronic MRCTs.
Authors: Denton E Connor; Jordan A Paulus; Parinaz Jila Dabestani; Finosh K Thankam; Matthew F Dilisio; R Michael Gross; Devendra K Agrawal Journal: J Bone Miner Metab Date: 2019-06-01 Impact factor: 2.626
Authors: Wei Lee Lim; Ling Ling Liau; Min Hwei Ng; Shiplu Roy Chowdhury; Jia Xian Law Journal: Tissue Eng Regen Med Date: 2019-06-26 Impact factor: 4.169
Authors: Nikoo Saveh Shemshaki; Ho-Man Kan; Mohammed Barajaa; Takayoshi Otsuka; Amir Lebaschi; Neha Mishra; Lakshmi S Nair; Cato T Laurencin Journal: Proc Natl Acad Sci U S A Date: 2022-08-08 Impact factor: 12.779
Authors: O Cases-Perera; C Blanco-Elices; J Chato-Astrain; C Miranda-Fernández; F Campos; P V Crespo; I Sánchez-Montesinos; M Alaminos; M A Martín-Piedra; I Garzón Journal: Sci Rep Date: 2022-06-15 Impact factor: 4.996
Authors: Antonio Marmotti; Giuseppe Maria Peretti; Silvia Mattia; Laura Mangiavini; Laura de Girolamo; Marco Viganò; Stefania Setti; Davide Edoardo Bonasia; Davide Blonna; Enrico Bellato; Giovanni Ferrero; Filippo Castoldi Journal: Stem Cells Int Date: 2018-07-30 Impact factor: 5.443